What is CeQur?
Established in 2008 and headquartered in Switzerland, CeQur is dedicated to the commercialization of sophisticated yet user-friendly insulin-delivery devices. The company's mission is to simplify therapy adherence for individuals living with diabetes, empowering them to maintain better control over their condition. By developing innovative solutions, CeQur addresses a critical need in diabetes care, aiming to improve the quality of life for patients through enhanced ease of use and efficacy in insulin administration.
How much funding has CeQur raised?
CeQur has raised a total of $491.6M across 5 funding rounds:
Series A
$29.6M
Series B
$27M
Series C
$215M
Private Equity
$120M
Series E
$100M
Series A (2010): $29.6M with participation from VI Partners and Endeavour Vision
Series B (2013): $27M, investors not publicly disclosed
Series C (2015): $215M supported by Endeavour Vision, Tandem Diabetes Care, Ypsomed, VI Partners, Arthurian Life Sciences, Woodford Investment Management, Kingdon Capital Management, Bank of Communications Schroder Fund Management Co. Ltd., Federated Hermes Kaufmann Funds, GMS Capital, and Credit Suisse
Private Equity (2025): $120M, investors not publicly disclosed
Series E (2026): $100M, investors not publicly disclosed
Key Investors in CeQur
VI Partners
VI Partners is the longest-established Swiss VC firm, with over 20 years of experience supporting innovative Healthcare and Technology companies. They have invested over CHF 250m in 55 ventures, initially advising the Venture Incubator fund and later establishing their own Swiss Innovation Fund.
Endeavour Vision
Endeavour Vision is a leading investment advisory firm specializing in transformative healthcare technologies, particularly in medical devices and digital health. They empower entrepreneurs to develop and commercialize innovative solutions that address critical unmet healthcare needs.
Woodford Investment Management
Woodford Investment Management is a financial services firm that managed various investment funds. While facing regulatory challenges and management changes, their focus was on providing managed investment solutions to clients.
What's next for CeQur?
The substantial enterprise-level funding and recent strategic investment indicate that CeQur is likely in a growth or scaling phase, poised for significant market expansion. This capital infusion is expected to fuel further product development, enhance manufacturing capabilities, and broaden market penetration. The company's focus on improving diabetes management through advanced delivery systems positions it for continued innovation and leadership in the healthcare technology sector. Future strategic moves may involve expanding its product portfolio or forging new partnerships to reach a wider patient base.
See full CeQur company page
